APDN Applied DNA Sciences Inc

Applied DNA Sciences, Inc. (OTCBB: APDN) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it has significantly expanded its office, production, and laboratory space and increased its personnel. The expansion reflects the company's continued worldwide growth in production capacity, technology advancement, and global customer support. Those factors are also seen in a steady rise in shipments of its DNA products, the core technology around which the company's authentication services are built.

The company's brick-and-mortar footprint has increased by well over 50% over the last year. The company has added nine positions in that time.

Dr. James A. Hayward, President and CEO of APDN, pointed out that the expansion has been driven in part by product shipments. "By the end of December, 2011, we recorded a substantial increase in our monthly shipments of DNA; as a result, our last two previously announced quarters were each record-setters. Incremental demand should be sustained as new opportunities are addressed."

Dr. Hayward concluded: "In addition to the current growth we are experiencing across the firm, our LMI-managed microchip project is leading the DOD's Defense Logistics Agency to seriously consider mandating SigNature® DNA for microcircuits. We are confident we can support a DOD mandate and continue to source additional candidates as this effort might expand.

"In addition, the initial responses to our new product lines, smartDNA® and digitalDNA™, have been encouraging. Our management team felt it appropriate to grow our resources at this time."

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 8, 2011 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Mitchell Miller 646-543-3373 fax: 631-444-8848 FCMN Contact: Email Contact Web site: http://www.adnas.com Twitter: @APDN, @APDNInvestor